Advanced search
Add to list

Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma

(2007) JOURNAL OF CLINICAL ONCOLOGY. 25(36). p.5770-5776
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
BOTTOMLEY, A, C COENS, F EFFICACE, et al. “Symptoms and Patient-reported Well-being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin with or Without Raltitrexed in Patients with Malignant Pleural Mesothelioma.” JOURNAL OF CLINICAL ONCOLOGY 25.36 (2007): 5770–5776. Print.
APA
BOTTOMLEY, A., COENS, C., EFFICACE, F., GAAFAR, R., MANEGOLD, C., BURGERS, S., VINCENT, M., et al. (2007). Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY, 25(36), 5770–5776.
Chicago author-date
BOTTOMLEY, A, C COENS, F EFFICACE, R GAAFAR, C MANEGOLD, S BURGERS, M VINCENT, C LEGRAND, and Jan Van Meerbeeck. 2007. “Symptoms and Patient-reported Well-being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin with or Without Raltitrexed in Patients with Malignant Pleural Mesothelioma.” Journal of Clinical Oncology 25 (36): 5770–5776.
Chicago author-date (all authors)
BOTTOMLEY, A, C COENS, F EFFICACE, R GAAFAR, C MANEGOLD, S BURGERS, M VINCENT, C LEGRAND, and Jan Van Meerbeeck. 2007. “Symptoms and Patient-reported Well-being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin with or Without Raltitrexed in Patients with Malignant Pleural Mesothelioma.” Journal of Clinical Oncology 25 (36): 5770–5776.
Vancouver
1.
BOTTOMLEY A, COENS C, EFFICACE F, GAAFAR R, MANEGOLD C, BURGERS S, et al. Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007;25(36):5770–6.
IEEE
[1]
A. BOTTOMLEY et al., “Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma,” JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 36, pp. 5770–5776, 2007.
@article{395254,
  author       = {BOTTOMLEY, A and COENS, C and EFFICACE, F and GAAFAR, R and MANEGOLD, C and BURGERS, S and VINCENT, M and LEGRAND, C and Van Meerbeeck, Jan},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  language     = {eng},
  number       = {36},
  pages        = {5770--5776},
  publisher    = {AMER SOC CLINICAL ONCOLOGY},
  title        = {Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma},
  volume       = {25},
  year         = {2007},
}

Web of Science
Times cited: